Cost-Effectiveness Analysis of Peginterferon Beta-1a in the Treatment of Relapsing-Remitting Multiple Sclerosis in Italy: Results of an Updated Analysis
DOI:
https://doi.org/10.7175/fe.v19i1.1385Keywords:
Cost-Effectiveness, Peginterferon Beta-1a, Multiple SclerosisReferences
Kobelt G, Pugliatti M. Cost of multiple sclerosis in Europe. Eur J Neurol 2005; 12 Suppl 1: 63-7; https://doi.org/10.1111/j.1468-1331.2005.01193.x
Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 2010; 9: A387-94; https://doi.org/10.1016/j.autrev.2009.11.010
Multiple Sclerosis International Federation. Atlas of MS 2013. Available at http://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf (last accessed September 2018)
Noyes K, Weinstock-Guttman B. Impact of diagnosis and early treatment on the course of multiple sclerosis. Am J Manag Care 2013; 19(17 Suppl): s321-31
Iannazzo S, Santoni L, Saleri C, et al. Cost-effectiveness analysis of peginterferon beta-1a in Italian relapsing remitting multiple sclerosis management. Farmeconomia. Health economics and therapeutic pathways 2016; 17(Suppl 2): 13-36; http://dx.doi.org/10.7175/fe.v17i2S.1230
Iannazzo S, Iliza AC, Perrault L. Disease-modifying therapies for multiple sclerosis: a systematic literature review of cost-effectiveness studies. Pharmacoeconomics 2018; 36: 189-204; https://doi.org/10.1007/s40273-017-0577-2
Peninsula Technology Assessment Group (PenTAG). The effectiveness and cost-effectiveness of natalizumab for multiple sclerosis: an evidence review of the submission from Biogen. Evidence Review Group Report commissioned by NHS R&D HTA Programme on behalf of: NICE, 2007. Available at https://www.nice.org.uk/guidance/ta127 (last accessed September 2018)
Calabresi PA, Deykin A, Arnold DL, et al. Analysis of 2-year clinical efficacy and safety of Peginterferon Beta-1a in patients with relapsing-remitting multiple sclerosis: data from the pivotal phase 3 ADVANCE study. American Academy of Neurology, 66th Annual Meeting. Philadelphia, 26 April-3 May 2014
Calabresi PA, Kieseier BC, Arnold DL, et al.; ADVANCE Study Investigators. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, doubleblind study. Lancet Neurol 2014; 13: 657-65; https://doi.org/10.1016/S1474-4422(14)70068-7
Tolley K, Hutchinson M, You X, et al. A network meta-analysis of efficacy and evaluation of safety of subcutaneous pegylated interferon beta-1a versus other Injectable therapies for the treatment of relapsing-remitting multiple sclerosis. PLoS One 2015: 1-21; https://doi.org/10.1371/journal.pone.0127960
Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Italy. Eur J Health Econ 2006; 7 Suppl 2: S45-54; http://dx.doi.org/10.1007/s10198-006-0385-7
National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2013. Available at http://www.nice.org.uk/article/pmg9/chapter/foreword (last accessed September 2018)
ISTAT. Consumer price index inflation to July 2018. Availabe at http://rivaluta.istat.it (last accessed September 2018)
Agenzia Italiana del Farmaco – AIFA. DETERMINA 31 maggio 2018. Rinegoziazione del medicinale per uso umano «Rebif», ai sensi dell’articolo 8, comma 10, della legge 24 dicembre 1993, n. 537. (Determina n. 866/2018). Italian Official Journal (Gazzetta Ufficiale) n. 145, June 25th, 2018
Battaglia M, Kobelt G, Ponzio M, et al.; European Multiple Sclerosis Platform. New insights into the burden and costs of multiple sclerosis in Europe: Results for Italy. Mult Scler 2017; 23(2_suppl):104-116
Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Italy. Mult Scler 2012; 18(2 Suppl): 29-34; https://doi.org/10.1177/1352458512441566c
AIFA. Reference list for generic products (Lista di trasparenza). Update 09/08/2018. Available at http://www.aifa.gov.it/content/liste-di-trasparenza-aggiornamento-del-09082018 (last accessed September 2018)
ISTAT. Mortality tables of the Italian general population. Year 2016. Available at http://demo.istat.it (last accessed September 2018)
Published
Issue
Section
License
>> DISTRIBUTION / LICENSE <<
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)
